SENTI-202 Achieves FDA Fast-Track Status as Senti Biosciences Advances Novel Cancer Therapy

Senti Biosciences has announced a significant milestone for its cutting-edge CAR-NK immunotherapy program. The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, marking accelerated regulatory recognition for this off-the-shelf cellular therapy targeting relapsed and refractory acute myeloid leukemia as well as additional hematologic malignancies.

The designation follows impressive Phase 1 clinical findings, which demonstrated that SENTI-202 can selectively eliminate leukemic cells while preserving the viability of normal hematopoietic stem cells—a critical safety profile for bone marrow-based cancers. This selectivity represents a key advantage in the development of next-generation CAR-NK platforms.

The regulatory advancement builds on Senti’s earlier acquisition of Orphan Drug Designation for SENTI-202, which was secured earlier in 2025. The company recently presented updated trial data from the Phase 1 program at the 2025 American Society of Hematology (ASH) Annual Meeting, where investor interest in the program appears to be building.

Market participants are taking note of the progress. SNTI shares reflected investor optimism, trading at $2.6083, representing a gain of $0.2183 or 9.13 percent on Nasdaq. The company has scheduled an investor webcast for December 9 to provide additional perspective on the clinical and commercial strategy surrounding SENTI-202’s development pathway.

The RMAT designation typically expedites interactions with regulatory authorities and may accelerate the overall timeline to clinical proof-of-concept, potentially positioning Senti’s CAR-NK platform as a meaningful competitive entry in the cell therapy space for hematologic malignancies.